Formerly known as CBT Pharmaceuticals.
At Apollomics, we are a purpose driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve.
Apollomics is committed to the discovery and development of oncology combination therapies. We believe that combination regimens can achieve clinically meaningful, durable responses that will allow us to enhance outcomes for patients. We have in-licensed our assets from multiple partners and built strong collaborations to advance our pre-clinical and clinical development programs. When developing an asset, we begin with rigorous IND-enabling studies to establish sound mechanistic and scientific rationale and guide our development path. This path may be as a monotherapy, a combination therapy, or both. While our ultimate goal is to study each of our assets in combination with other agents, we have developed a broad portfolio of single agent and combination trials.
Location: United States, California, Foster City
Employees: 51-200
Total raised: $224M
Founded date: 2016
Investors 7
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.11.2020 | Series C | $124M | - |
| 08.01.2019 | Series B | $100M | - |
Mentions in press and media 9
| Date | Title | Description |
| 06.11.2020 | US biopharmaceutical firm Apollomics raises $124m led by Ping An Capital | Premium Apollomics, Inc., an incubator project by US healthcare fund manager OrbiMed Asia, announced on Friday that it has raised $124.2 million in a Series C round of financing led by China’s Ping An Insurance Group’s investment vehicle Pi... |
| 06.11.2020 | US biopharmaceutical firm Apollomics raises $124m led by Ping An Capital | Apollomics, Inc., an incubator project by US healthcare fund manager OrbiMed Asia, announced on Friday that it has raised $124.2 million in a Series C round of financing led by China’s Ping An Insurance Group’s investment vehicle Ping An Ca... |
| 09.01.2019 | Term Sheet — Wednesday, January 9 | AN IPO FREEZE Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop We were supposed to kick off 2019 with a wave of IPOs, including some of the biggest tech offerings we’ve seen in years. W... |
| 09.01.2019 | Apollomics Raises $100M Series B | FOSTER CITY, CA, Apollomics today announced it has raised $100 million in a Series B financing. >> Click here for more funding data on Apollomics >> To export Apollomics funding data to PDF and Excel, click here Apollomic... |
| 08.01.2019 | Top startup news for today, Tuesday, January 8, 2019 | Good morning! Here are some of the top technology startup news stories for today, Tuesday, January 8. Dutch startup CryptoHopper brings Advanced Automated Cryptocurrency Trading to the masses with strategy marketplace. Cryptohopper, today ... |
| 08.01.2019 | Apollomics Raises $100M in Series B Financing | Apollomics, Inc. (fka CBT Pharmaceuticals, Inc.), a Foster City, CA-based innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies, raised $100m in a Series B financing. The round was... |
| 08.01.2019 | Daily funding roundup - January 8th, 2019 | LendingFront raised $4M; Headset raised $12.1M; Managed by Q raised $25M; Humatics raised $28M Carson Living: Carson is a real estate tech startup that provides services to unstaffed residential buildings. Carson has raised $3 million in se... |
| 08.01.2019 | Apollomics raises $100M to fund transpacific cancer R&D plan W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Apollomics has raised $100 million to fund a multifront oncology clinical trial program while moving its headquarters from China to California. The series B round sets Apollomics up to advance its c-Met inhibitor and pipeline of other clini... |
| 08.01.2019 | Apollomics raises $100M to fund transpacific cancer R&D plan | Apollomics has raised $100 million to fund a multifront oncology clinical trial program while moving its headquarters from China to California. The series B round sets Apollomics up to advance its c-Met inhibitor and pipeline of other clini... |